Y Intercept Hong Kong Ltd Sells 6,229 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Y Intercept Hong Kong Ltd decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 7.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 83,123 shares of the biotechnology company’s stock after selling 6,229 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BioCryst Pharmaceuticals were worth $632,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in BCRX. Mirae Asset Global Investments Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,322 shares during the last quarter. Xponance Inc. grew its stake in shares of BioCryst Pharmaceuticals by 13.1% in the second quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 1,505 shares during the last quarter. Captrust Financial Advisors increased its holdings in BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,644 shares during the period. Creative Planning raised its position in BioCryst Pharmaceuticals by 5.9% during the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock valued at $375,000 after purchasing an additional 2,734 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in BioCryst Pharmaceuticals by 7.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 51,012 shares of the biotechnology company’s stock worth $388,000 after buying an additional 3,653 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Down 0.9 %

BCRX opened at $7.53 on Friday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $8.88. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -12.34 and a beta of 1.79. The stock has a fifty day simple moving average of $7.61 and a two-hundred day simple moving average of $7.39.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same period last year, the business earned ($0.19) earnings per share. The company’s revenue was up 35.1% on a year-over-year basis. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays boosted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $15.60.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.